CHNC China Infrastructure Construct

Cannabis Bioscience International Holdings (CBIH) Unveils Its Rebranding Through Its New and Innovative Website

Cannabis Bioscience International Holdings (CBIH) Unveils Its Rebranding Through Its New and Innovative Website

HOUSTON, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via -- Cannabis Bioscience International Holdings (trading on the OTC Markets under the ticker symbol CBIH), a medical research company that specializes in clinical trials and cannabinoids education, proudly announces the launch of its new website as a part of its bold rebranding strategy.

The new web page better represents the company’s values and vision, predominantly in the areas of research and production of cannabis as medicine. In particular with its purpose of providing patients with healing alternatives when struggling with chronic conditions, inflammatory diseases, and side effects of opioids and other traditional treatments. Additionally, the new website is expected to be an important step forward for the relationship of the company with its Investors and those interested in being involved. The rebranding efforts at CBIH encompass several exciting elements, including: a scientific design concept, sources for qualified investors, a new corporate email, and clear information about who the company is, what is it doing, and what the future plans are.

The new CBIH website link is . “This new website undoubtedly represents our scientific spirit. We invite qualified investors to review the presentation of the projects that the company expects to develop in the next 5 years, including the selection of some of the product formulations that the company owns. We also make public that investors and interested parties may contact the company directly through the new e-mail ,” mentioned Henry Levinski, VP/Treasurer of CBIH.

By defining the brand identity, the company strives to position itself as the market leader for cannabinoid data clinical studies and a harborage for those patients that traditional medicine has forgotten.

For more information contact us at:

817/528-2475 for English

214/733-0868 for Spanish

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at .



EN
11/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 ...

Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.CBIH clarifies that this communication reflects a serious corporate and executive planning approach intended to protect business value and accelerate operati...

 PRESS RELEASE

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr....

Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.CBIH confirms receipt of a communication from the Centers for Medicare & Medicaid Services (CMS) acknowledging Company's meeting request with CMS Administrator Dr. Mehmet Oz a...

 PRESS RELEASE

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accele...

Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to resche...

 PRESS RELEASE

CBIH Announces New Patent Initiative Targeting Opioid Addiction Throug...

Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States.According to U.S. public health data, more than 700,000 people have died from opioid-involved overdoses since the early 2000s. Despite recent progress, the crisis remains severe: in 2024 alone, a...

 PRESS RELEASE

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Op...

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate.After eighteen years of navigating scientific challenges, market volatility, stigma, and regulatory uncertainty, CBIH stated that this turn...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch